-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment

Dow Jones·06/16/2025 13:35:00

Please log in to view news